Therapy with intermittent pulse cyclophosphamide for pulmonary hypertension associated with systemic lupus erythematosus

Lupus

Volumn 13, Issue 2, 2004, Pages 105-112

  Gonzalez Lopez, Laura ^a,e   Cardona Munoz E G ^a   Celis, A ^b   Garcia De La Torre I ^c   Orozco Barocio, G ^c   Salazar Paramo, M ^b   Garcia Gonzalez, C ^b   Garcia Gonzalez, A ^b   Sanchez Ortiz, A ^a   Trujillo Hernandez, B ^d   Gamez Nava, J I ^b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b HOSPITAL DE ESPECIALIDADES   (Mexico)

^c SECRETARÍA DE SALUD   (Mexico)

^d UNIVERSIDAD DE COLIMA   (Mexico)

^e University of Colima ^*  (Mexico)

Author keywords

Cyclophosphamide; Pulmonary hypertension; SLE

Indexed keywords

CYCLOPHOSPHAMIDE; ENALAPRIL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; HEART FUNCTION; HUMAN; HYPOTENSION; INFECTION; LEUKOPENIA; LUNG ARTERY PRESSURE; MALE; NAUSEA; PNEUMONIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CYCLOPHOSPHAMIDE; ENALAPRIL; HUMANS; HYPERTENSION, PULMONARY; INJECTIONS, INTRAVENOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; PULSE THERAPY, DRUG; TREATMENT OUTCOME;

EID: 10744228876     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203304lu509oa     Document Type: Article

References (39)

1. Perez D, Kramer N. Pulmonary hypertension in systemic lupus erythematosus: Report of four cases and review of literature. Semin Arthritis Rheum 1981; 11: 177-181.
2. Asherson RA, Hackett D, Gharavi AE, Harris EN, Kennedy HG, Hughes GRV. Pulmonary hypertension in systemic lupus erythematosus: A report of three cases. J Rheumatol 1986; 13: 416-420.
3. Asherson RA, Oakley CM. Pulmonary hypertension and systemic lupus erythematosus. J Rheumatol 1986; 13: 1-5.
4. Shen JY, Chen SL, Wu YX et al. Pulmonary hypertension in systemic lupus erythematosus. Rheumatol Int 1999; 18: 147-151.
5. Simonson JS, Schiller NB, Petri M, Hellmann DB. Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 1989; 16: 918-925.
6. Winslow TM, Ossipov MA, Fazio GP, Simonson JS, Redberg RF, Schiller NB. Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am Heart J 1995; 129: 510-515.
7. Asherson RA, Higenbottam TW, Dinh Xuan AT, Khamashta MA, Hughes GRV. Pulmonary hypertension in a lupus clinic: Experience with twenty-four patients. J Rheumatol 1990; 17: 1292-1298.
8. Asherson RA. Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 1990; 17: 414-415.
9. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
10. Krowka MJ. Pulmonary hypertension: Diagnostic and therapeutics. Mayo Clin Proc 2000; 75: 625-630.
11. Raeside D, Peacock A. Making measurements in the pulmonary circulation: when and how? Thorax 1997; 52: 9-11.
12. Sanchez O, Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax 1999; 54: 273-277.
13. Alpert MA, Pressly TA, Mukerji VM, Lambert CR, Mukerji B. Short-and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease. Chest 1992; 102: 1407-1412.
14. Niarchos AP, Whitman HH, Goldstein JE, Laragh JH. Hemodynamic effects of captopril in pulmonary hypertension of collagen vascular disease. Am Heart J 1982; 104: 834-838.
15. Escudero J, Navarro J, Padura A, Betancourt L, Nava G. Use of enalapril, an angiotensin-converting enzyme inhibitor, in pulmonary artery hypertension. Arch Inst Cardiol Mex 1986; 56: 467-473.
16. Gourley MF, Austin HA, Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med 1996; 125: 549-557.
17. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991; 34: 945-950.
18. Boumpas DT, Yamada H, Patronas NJ, Scott D, Klippel JH, Balow JE. Pulse cyclophosphamide for severe neuropsychiatric lupus. QJM 1991; 296: 975-84.
19. Neuwelt CM, Lacks S, Kayle BR, Ellman JB, Borenstein DG. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995; 98: 32-41.
20. Dhal M, Chalmers A, Wade J, Calverley D, Munt B. Ten year survival of a patient with advanced pulmonary hypertension and mixed connective tissue disease treated with immunosuppressive therapy. J Rheumatol 1992; 19: 1807-1809.
21. Groen H, Bootsma H, Postma DS, Kallenberg CGM. Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide. J Rheumatol 1993; 20: 1055-1057.
22. Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 2002; 29: 282-287.
23. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
24. Hatle L, Angelsen B eds. Doppler Ultrasound in Cardiology: Physical Principles and Clinical Applications, 2nd ed. Philadelphia: Lea and Febiger, 1985.
25. Guzmán J, Cardiel MH, Arce-Salinas A, Sanchez-Guerrero J, Alarcon-Segovia D. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 1992; 19: 1551-1558.
26. Loizou S, McCrea JD, Rudge AC, Reynolds R, Boyle CC, Harris EN. Measurement of anticardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): Standardization and quantification of results. Clin Exp Immunol 1985; 62: 738-745.
27. Illei GG, Austin HAIII, Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001; 135: 248-257.
28. Quismorio FP Jr, Sharma O, Koss M et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 1984; 13: 349-359.
29. Yeo PP, Sinniah R. Lupus cor pulmonale with electron microscope and immunofluorescent antibody studies. Ann Rheum Dis 1975; 34: 457-460.
30. Fayemi AO. Pulmonary vascular disease in systemic lupus erythematosus. Am J Clin Pathol 1976; 65: 284-290.
31. Yoshio T, Masuyama J, Sumiya M, Minota S, Kano S. Antiendothelial cell antibodies and their relation to pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 1994; 21: 2058-2063.
32. McCune WJ, Golbus J, Zeldes W, Bohlke P, Dunne R, Fox DA. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988; 318: 1423-1431.
33. Schuster DP, Crouch EC, Parks WC, Johnson T, Botney MD. Angiotensin converting enzyme expression in primary pulmonary hypertension. Am J Respir Crit Care Med 1996; 154: 1087-1091.
34. Pollman MJ, Yamada T, Horiuchi M, Gibbons GH. Vasoactive substances regulate vascular smooth muscle cell apoptosis: Countervailing influences of nitric oxide and angiotensin II. Circ Res 1996; 79: 748-756.
35. Schindler R, Dinarello CA, Koch KM. Angiotensin-converting-enzyme inhibitors suppress synthesis of tumour necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine 1995; 7: 526-533.
36. Fukuzawa M, Satoh J, Sagara M et al. Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo. Immunopharmacology 1997; 36: 49-55.
37. Mancini GB. Long-term use of angiotensin-converting enzyme inhibitors to modify endothelial dysfunction: a review of clinical investigations. Clin Invest Med 2000; 23: 144-161.
38. Gonzalez-Lopez L, Gamez-Nava JI, Cardona-Muñoz E, Blanco-Turbay R, Suarez-Almazor ME, Ramos-Remus C. Impact of pulmonary hypertension (PH) on patients with systemic lupus erythematosus (SLE) compared with controls. Results of a 3.5 year prospective cohort. Arthritis Rheum 1997; 40: S106 (abstract).
39. Magliano M, Isenberg DA, Hillson J. Pulmonary hypertension in autoimmune rheumatic diseases. Where are we now? Arthritis Rheum 2002; 46: 1997-2009.